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Clinics and pathology 
Disease 
M1 acute myeloid leukemia 
Epidemiology 
Only one case to date, a 29-year-old female patient 
(Fu et al., 2003; also reported in Shih et al., 2006). 
Evolution 
The patient achieved complete remission (CR) with 
chemotherapy and remained in CR for 25 months. 
Cytogenetics 
Cytogenetics morphological 
Cryptic translocation, missed by cytogenetic analysis.  
The karyoptype showed a trisomy 22 and 3 marker 
chromosomes. 
Genes involved and 
proteins 
MLL starts at 118307.205 from pter, and CBL at 
119076.986; they are normally separated by 29 
known genes, which were apparently deleted in the 






A major transcript of 14982 bp produces a 3969 
amino acids protein from 36 of the 37 exons. 
Contains from N-term to C-term a binding site for 
MEN1, 3 AT hooks (binds to the minor grove of 
DNA); 2 speckled nuclear localisation signals; 2 
repression domains RD1 and RD2: RD1 or CXXC: 
cystein methyl transferase, binds CpG rich DNA, has
a transcriptional repression activity; RD2 recruits 
histone desacetylases HDAC1 and HDAC2; 3 plant 
homeodomains (cystein rich zinc finger domains, 
with homodimerization properties), 1 bromodomain 
(may bind acetylated histones), and 1 plant 
homeodomain; these domains may be involved in 
protein-protein interaction; a FYRN and a FRYC 
domain; a transactivation domain which binds CBP; 
may acetylates H3 and H4 in the HOX area; a SET 
domain: methyltransferase; methylates H3, including 
histones in the HOX area for allowing chromatin to 
be open to transcription. MLL is cleaved by taspase 1 
into 2 proteins before entering the nucleus: a 
p300/320 N-term protein called MLL-N, and a p180 
C-term protein, called MLL-C. The FYRN and a 
FRYC domains of native MLL associate MLL-N and 
MLL-C in a stable complex; they form a multiprotein 
complex with transcription factor TFIID.  
General transcription factor; maintains HOX genes 
expression in undifferentiated cells. Major regulator 
of hematopoiesis and embryonic development; role in 
cell cycle regulation. 
 













Characterized by an N-terminal phosphotyrosine 
kinase-binding domain involved in protein-protein 
interaction, a short linker region, a zinc-binding 
RING-finger domain mediating the E3 ubiquitin 
ligase activity, proline-rich regions which mediate 
interactions with SH3-domain-containing proteins, 
and a C-terminal UBA (ubiquitin-associated) domain 
which enables homodimer formation, and also 
interacts with ubiquitin.  
CBL is a member of the family of E3 ubiquitin 
ligases (CBL, CBLB and CBLC) that negatively 
regulates many signaling pathways downstream of 
membrane receptor tyrosine kinases, and also some 
non-receptor tyrosine-protein kinase (e.g. HCK). 
CBL is an adaptor protein. CBL forms the "CBL 
interactome" with associated proteins such as 
ubiquitin, SH3KBP1/CIN85, 
ARHGEF7/COOL1/PIXB, PDCD6IP/ALIX/AIP1, 
and TSG101.  
CBL is a regulator of cell growth, through the 
regulation of pathways such as PI3K/AKT/MTOR 
and RAS/RAF/MAPK. Acts as a tumor-suppressor 




Mutations located in the RING finger domain or the 
linker region were found in a syndrome with clinical 
features overlapping Noonan syndrome (Martinelli et 
al., 2010). 
Somatic mutations 
CBL mutations have been found in 
myeloproliferative/myelodysplastic syndromes, 
causing the loss of its E3-ubiquitin ligase activity, 
and an increase in cell proliferation (Aranaz et al.,
2012). 




5'MLL-3'CBL; breakpoint in exon 9 of MLL and 
exon 8 of CBL. 
Fusion protein 
Description 
Joins amino acid (aa) 1362 from MLL to aa 477 from 
CBL. The fusion protein is made of 1791 aa (1362 
from MLL and 429 from CBL). It contains the AT 
hooks, Pro-rich, and the Zn finger CXXC type 
domains from MLL in N-term, and the Pro-rich and 
UBA domains from CBL in C-term. 
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